139 related articles for article (PubMed ID: 10456263)
1. Advances in the molecular basis of renal neoplasia.
Cohen HT
Curr Opin Nephrol Hypertens; 1999 May; 8(3):325-31. PubMed ID: 10456263
[TBL] [Abstract][Full Text] [Related]
2. Genetics of renal tumours.
Fleming S
Cancer Metastasis Rev; 1997 Jun; 16(1-2):127-40. PubMed ID: 9156283
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
4. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
5. The genetic basis of cancer of the kidney.
Linehan WM; Walther MM; Zbar B
J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
8. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
Lemm I; Lingott A; Pogge v Strandmann E; Zoidl C; Bulman MP; Hattersley AT; Schulz WA; Ebert T; Ryffel GU
Mol Carcinog; 1999 Apr; 24(4):305-14. PubMed ID: 10326868
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
11. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
12. Inherited renal cancer.
Turner KJ
BJU Int; 2000 Jul; 86(2):155-64;quiz i. PubMed ID: 10886102
[No Abstract] [Full Text] [Related]
13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
14. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
15. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
16. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic mechanism of the kidney cancer].
Nakaigawa N; Yao M; Kishida T; Kubota Y
Nihon Rinsho; 2001 Jan; 59(1):104-9. PubMed ID: 11197838
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.
Hewitt SM; Hamada S; McDonnell TJ; Rauscher FJ; Saunders GF
Cancer Res; 1995 Nov; 55(22):5386-9. PubMed ID: 7585606
[TBL] [Abstract][Full Text] [Related]
20. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]